Future of Oral Antidiabetic Drugs Market: Size, Share & Forecasts to 2029

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

What Is the Projected Market Size Valuation of the Oral Antidiabetic Drugs Market by 2025?
In recent times, there has been robust growth in the market size of oral antidiabetic drugs. The market, which was valued at $62.25 billion in 2024, will witness an increase, reaching $66.73 billion in 2025, representing a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this historic growth include the increasing instances of diabetes, enhanced awareness about diabetes control and management, an uptick in the ageing population, expanded availability of contemporary oral antidiabetic drugs, and the development of healthcare infrastructure.

What Is the Estimated Market Growth Value for the Oral Antidiabetic Drugs Industry in 2029?
Strong advancement is expected in the oral antidiabetic drugs market with an estimated growth to $86.92 billion by 2029, at a compound annual growth rate (CAGR) of 6.8%. The growth factors contributing to this projected increase include the rising acceptance of innovative oral antidiabetic treatments, an increase in research and development investments in diabetes, growing demand for affordable diabetes solutions, a surge in type 2 diabetes cases globally, and a heightened focus on personalized healthcare for diabetes patients. Significant trends for this period encompass developments in drug delivery methods, innovations in combined therapies, the integration of digital health aides for diabetes control, creation of safer, more efficacious oral antidiabetic medications, and advancement in tailored treatment strategies.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/oral-antidiabetic-drugs-global-market-report

What Are the Growth Drivers and Opportunities in the Oral Antidiabetic Drugs Market?
The increasing type 2 diabetes is expected to propel the growth of the oral antidiabetic drugs market going forward. Type 2 diabetes refers to a chronic condition where the body either resists insulin or doesn't produce enough to maintain normal glucose levels. The rise in type 2 diabetes is due to the increasing obesity rates, as excess body fat results to insulin resistance and impaired glucose regulation. Oral antidiabetic drugs help manage type 2 diabetes by improving insulin sensitivity, enhancing insulin secretion, or reducing glucose production and absorption, thereby maintaining optimal blood sugar levels. For instance, in March 2025, according to the Office for Health Improvement and Disparities, a UK-based government agency, reported that type 2 diabetes prevalence in adults aged 17+ in England rose to 7.0%, up from 6.8% in March 2023. Therefore, increasing type 2 diabetes is propelling growth of the oral antidiabetic drugs market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25854&type=smp

What Are the Primary Segments Covered in the Global Oral Antidiabetic Drugs Market Report?
The oral antidiabetic drugs market covered in this report is segmented -

1) By Drug Class: Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Sodium Glucose Transport Protein -2 Inhibitors, Sulfonylureas, Thiazolidinediones, Megalitinides, Alpha Glucosidase Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Sublingual, Buccal
3) By Therapeutic Area: Type 2 Diabetes, Gestational Diabetes, Type 1 Diabetes
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels
5) By End User: Hospitals, Pharmact Store, Drug Store, Diabetes Treatment Centers, Other End Users

Subsegments:
1) By Biguanides: Metformin Hydrochloride, Metformin Extended Release, Combination Products
2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin
3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin
4) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide
5) By Thiazolidinediones: Pioglitazone, Rosiglitazone
6) By Meglitinides: Repaglinide, Nateglinide
7) By Alpha Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose
8) By Other Drug Classes: Bromocriptine, Colesevelam

What Are the Top Growth Trends in the Oral Antidiabetic Drugs Market?
Leading entities in the oral antidiabetic drugs market are keen on conducting clinical trials in their bid to create safer and more efficient treatment methods, expand their range of products, and secure approvals for advanced therapies from relevant regulatory bodies. Clinical trials are strictly regulated research initiatives which are implemented on human subjects with the motive of assessing the security, efficacy, and potential side effects of fresh medical treatments, drugs, or interventions. For example, in April 2025, Eli Lilly and Company, a pharmaceutical firm based in the US, unveiled Orforglipron, a once-daily oral GLP-1 receptor agonist developed to simplify diabetes management through a triumphant phase 3 trial. This oral treatment is designed to offer efficacy and safety that is on par with injectable variants, in addition to improving patient compliance. Clinical trials revealed that orforglipron brought down HbA1c (an indicator of blood sugar regulation) by an average of 1.3% to 1.6% across various doses for a period of 40 weeks.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25854&type=smp

Which Companies Are Shaping the Future of the Oral Antidiabetic Drugs Market?
Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited

Which Region Holds the Largest Market Share in the Oral Antidiabetic Drugs Industry?
North America was the largest region in the oral antidiabetic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral antidiabetic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.